Company Overview Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease ( IBD ) and rheumatic diseases. Spyre s pipeline includes extended half-life antibodies targeting 4 7, TL1A, and IL-23 in development as monotherapies and pair-wise combinati…
Negative free cash flow of -$169M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$0.00
Net Income (TTM)
-$179M
▲ +25.4% YoY
Op. Margin
—
ROIC
-27.74%
▲ +20.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$186M
▼ -7.5% YoY
Op. Cash Flow (TTM)
-$186M
▼ -7.5% YoY
Net Debt
-$741M
Net Cash Position
Cash & Equiv.
$741M
Continue Research